凱旺科技(301182.SZ):在超導材料方面未取得實際成果,公司目前已經調整了研究方向
格隆匯8月2日丨有投資者向凱旺科技(301182.SZ)提問,“公司旗下研究院有無針對超導材料技術的研究和應用?”,公司子公司河南凱旺新材料研究院在成立初期在研究方向上有石墨烯及超導材料相關領域的佈局,隨着公司的發展及各項技術研究的深入,公司在新材料連接器方面取得有效成果,在超導材料方面未取得實際成果,公司目前已經調整了研究方向,公司具體的公司經營範圍及研究方向可以查詢公司研究院的經營範圍。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.